Aphria CEO shares info on Tetra Bio Pharma during Q1 2019 results

Aphria owns 10 million common shares of Tetra Bio Pharma at cost of $2,300, with fair value of $11,000 as at August 31, 2018.

Excerpt from Aphria’s Q1 report conference call today

We maintain a strong relationship with TBP.

In addition to being a member of their board of directors, including Chair of the Audit Committee, and Aphria being a large shareholder, we maintain a supply contract with TBP for two products which they are performing clinical trials on – PPP001, a compressed dried flower product that is smoked, and PPP005 – an oil based product that is delivered with a syringe in the mouth.

Tetra has many interesting trials going on currently, including a recent announcement of a head-to-head study on pain management for PPP001 against Fentanyl.

In addition to the Fentanyl study, PPP001 is currently in Phase 3, with the end goal being a DIN.

We see enormous opportunity for our relationship with Tetra, both as a supplier and as a shareholder.

 

 

One thought on “Aphria CEO shares info on Tetra Bio Pharma during Q1 2019 results

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s